<DOC>
	<DOCNO>NCT01453907</DOCNO>
	<brief_summary>This study determine safety PK single IV dose ETI-204 subject 18 65 year age . Three cohort study subject receive ETI-204 . This study randomize , double-blind stratified gender . Each cohort contain 36 subject ( include least four female ) , 30 receive ETI-204 six receive placebo .</brief_summary>
	<brief_title>Placebo-Controlled , Sequential Group , Single Dose , Dose-Escalation Study Evaluate Safety PK ETI-204</brief_title>
	<detailed_description>Protocol AH-105 single center , randomize , double-blind , placebo-controlled , sequential , dose escalation study . It evaluate safety PK single IV dose ETI-204 administer approximately 108 healthy male female subject . At dose level , 30 healthy subject , include least 4 female , randomly assign active drug , least 6 healthy subject gender randomly assign match placebo . Description Agent : ETI-204 monoclonal antibody ( mAb ) protective antigen ( PA ) Bacillus anthracis . The study consist 3 phase : Screening , Inpatient , Outpatient Follow-up . Enrollment criterion determine 21-day Screening Phase ( Visit 1 ) , follow 3 night inpatient phase eligible subject receive single dose IV ETI-204 match placebo describe undergo routine safety monitoring , dermatologic assessment , blood draw pre-specified time point . Subjects discharge center collection 48-hour PK sample . During subsequent 70-day outpatient follow-up phase , subject return center Days 8 , 15 , 29 , 43 71 clinical laboratory testing ( hematology clinical chemistry ) , physical examination vital sign measurement , routine safety monitoring . Blood sample PK anti-drug antibody ( ADA ) also collect . The 70 day post-dosing follow-up study select allow characterization PK profile ETI-204 potential development ADA .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<criteria>Subjects meet criterion show may include study . 1 . Healthy male female subject 18 65 year age . 2 . Subjects body mass index ( BMI ) &gt; 18.5 &lt; 35 kg/m2 . 3 . Female subject childbearing potential ( postmenopausal surgically sterile ) must negative urine Î²hCG pregnancy test Screening . 4 . Female subject childbearing potential ( postmenopausal surgically sterile ) must use medically accept method contraception duration study , include 70day followup period . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) hormonal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . 5 . Male subject must agree practice abstinence use condom spermicide duration study , include 70day followup period . 6 . The subject clinically significant abnormality clinical laboratory test ( hematology , clinical chemistry , urinalysis ) ECG Screening . 7 . Subject provide write informed consent . Subjects meet criterion exclude participation study . 1 . Subject require regular use medication chronic condition . 2 . Subject clinically significant comorbidity would interfere completion study procedures objective , would compromise subject 's safety . 3 . Subject systolic blood pressure ( BP ) &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg . 4 . Subject systolic BP &lt; 90 mm Hg . 5 . Subject current suspect drug alcohol abuse specify Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) ( American Psychiatric Association 2000 ) . 6 . Subject positive alcohol drug test result Screening Day 1 7 . Subject receive investigational agent within 30 day 5 halflives ( whichever longer ) Screening . 8 . Subject congenital acquire immunodeficiency syndrome . 9 . Subject positive test Hepatitis B ( surface antigen ) , Hepatitis C , human immunodeficiency virus ( HIV ) Screening . 10 . Subject smoke &gt; 3 cigarette per day . 11 . Subject ever prior treatment anthrax exposure , prior anthrax infection , prior immunization anthrax vaccine prior treatment investigational anthrax treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>